Public market insider buying at Cardiol Therapeutics (CRDL)

Public market insider buying at Cardiol Therapeutics (T:CRDL)

Guillermo Torre, a Senior Officer, acquired 66,800 Common Shares (Class A) on a direct ownership basis at prices ranging from US$1.439 to US$1.458 between March 30th, and 31st, 2022. This represents a $121,173 investment into the company's shares and an account share holdings change of greater than 100%.

Cardiol Therapeutics is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Cardiol Therapeutics Inc. (Cardiol) is a Canada-based clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). The Company's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.